Today’s top gainers include the company Medivation, Inc. (NASDAQ:MDVN) which is in the industry Biotechnology, gaining 0.28% today. In the last week its performance is -1.59%, and 25.44% for the past quarter. Currently, Medivation, Inc., MDVN has a target price of 64.65, so today’s gain of 0.28% is a significant step towards its target price. The GAP today is therefore 0.55%.
Medivation, Inc. (NASDAQ:MDVN), has a market cap of 10268.6, and is based in USA. Insider ownership is at 1.20%, and institutional ownership is 92.70%.
At the current price of 61.74, it has a dividend yield of *TBA, and its target price is 64.65. This is with a profit margin of 25.40%, and total debt/equity of 0. Medivation, Inc. (NASDAQ:MDVN) has a P/E of 43.17, as well as a forward P/E of 27.67.
With a current EPS of 1.43, and a forecasted EPS growth for next year at 71.22%,Medivation, Inc. (NASDAQ:MDVN) has had a EPS growth for the past five years at 50.90%. For the next five years EPS growth is projected to be 35.15%.
Performance for the year is 10.65%. Since its IPO date on 1/13/1997, the total performance to date is 27.72%.
Volume today for Medivation, Inc. (NASDAQ:MDVN), is 976300, while its average volume is 2994.16. Whilst the total gain today was 0.28%, it did have a day high of -1.97%.
Volatility for this week has been at 1.23%, and 2.01% for the month. The 52-week low for Medivation, Inc., MDVN has been 133.78%, while the 52-week-high has reached -1.97%.
Looking at its return of investments, which is 27.10%, and its return on assets is 21.50%. Medivation, Inc. (NASDAQ:MDVN) has an operating margin of 40.20%. With a sales growth of 41.30% quarter over quarter. Bearing in mind that Medivation, Inc., MDVN is in the sector Healthcare, its long-term debt/equity is 0, and has a current ratio of 4.2 and 4.2 for quick ratio.
So what is the value of Medivation, Inc.? Well its PEG is 1.23, and the P/S is 10.3, along with a P/B of 11.27. Meanwhile it has a p/cash of *TBA.